Minireview: the OPG/RANKL/RANK system.
暂无分享,去创建一个
[1] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[2] D. Lacey,et al. The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development , 2000, Cell.
[3] Makoto Sato,et al. Targeted Disruption of Cbfa1 Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts , 1997, Cell.
[4] D L Lacey,et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[5] Brian R. Wong,et al. TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.
[6] T. Martin,et al. Osteoblastic cells are involved in osteoclast formation. , 1988, Endocrinology.
[7] S. K. Lee,et al. Printed in U.S.A. Copyright © 1999 by The Endocrine Society Parathyroid Hormone Stimulates TRANCE and Inhibits Osteoprotegerin Messenger Ribonucleic Acid Expression in Murine Bone Marrow Cultures: Correlation with , 2022 .
[8] B. Komm,et al. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. , 1988, Science.
[9] Josef M. Penninger,et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.
[10] D. Lacey,et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. , 1999, Endocrinology.
[11] S. Mochizuki,et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. , 1997, Biochemical and biophysical research communications.
[12] T. Martin,et al. Modulation of osteoclast differentiation. , 1992, Endocrine reviews.
[13] S. Ikuyama,et al. Glucocorticoid-induced osteoporosis: pathogenesis and management , 2000, Journal of Bone and Mineral Metabolism.
[14] T. Komori,et al. Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF). , 1998, Biochemical and biophysical research communications.
[15] B. Riggs,et al. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. , 2000, Endocrinology.
[16] R. Appleyard,et al. Osteoporosis influences the early period of fracture healing in a rat osteoporotic model. , 2000, Bone.
[17] E. Chen,et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. , 1987, Science.
[18] R. Kitazawa,et al. Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene. , 1999, Biochimica et biophysica acta.
[19] J. Glowacki,et al. Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. , 2000, Biochemical and biophysical research communications.
[20] G. Karsenty,et al. Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation , 1997, Cell.
[21] M. Goto,et al. Characterization of Structural Domains of Human Osteoclastogenesis Inhibitory Factor* , 1998, The Journal of Biological Chemistry.
[22] D. Lacey,et al. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells , 1999 .
[23] R. Wallace,et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis , 2000, Nature Genetics.
[24] S. Morony,et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.
[25] E. Clark,et al. Osteoprotegerin Is an αvβ3-induced, NF-κB-dependent Survival Factor for Endothelial Cells* , 2000, The Journal of Biological Chemistry.
[26] P. Mantyh,et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord , 2000, Nature Medicine.
[27] S. Manolagas,et al. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. , 2000, Endocrine reviews.
[28] K. Mann,et al. Evidence of estrogen receptors in normal human osteoblast-like cells. , 1988, Science.
[29] S. Morony,et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.
[30] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[31] B. Lanske,et al. PTH/PTHrP Receptor in Early Development and Indian Hedgehog--Regulated Bone Growth , 1996, Science.
[32] J. Pike,et al. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[33] S. Reddy,et al. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. , 2000, The Journal of clinical investigation.
[34] A. Nakanishi,et al. The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[35] G. Mundy,et al. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF–β , 1996, Nature Medicine.
[36] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[37] R. Steinman,et al. TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.
[38] D. Murray,et al. Rheumatoid arthritis synovial macrophage–osteoclast differentiation is osteoprotegerin ligand‐dependent , 2000, The Journal of pathology.
[39] B. Riggs,et al. Regulation of osteoclastogenesis and RANK expression by TGF‐β1 , 2001 .
[40] R. Dubose,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.
[41] D. Lacey,et al. Printed in U.S.A. Copyright © 1999 by The Endocrine Society Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in , 2022 .
[42] S. Morony,et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[43] P. Sexton,et al. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. , 1986, The Journal of clinical investigation.
[44] S. Mochizuki,et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. , 1998, Endocrinology.
[45] A. C. Webb,et al. Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[46] T. Martin,et al. Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[47] Paul J. Williams,et al. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. , 2001, Cancer research.
[48] F. Ross,et al. Estrogen Decreases Osteoclast Formation by Down-regulating Receptor Activator of NF-κB Ligand (RANKL)-induced JNK Activation* , 2001, The Journal of Biological Chemistry.
[49] K Yano,et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. , 1998, Biochemical and biophysical research communications.
[50] Toshio Matsumoto,et al. 17β-Estradiol Stimulates Expression of Osteoprotegerin by a Mouse Stromal Cell Line, ST-2, via Estrogen Receptor-α. , 2001, Endocrinology.
[51] S. Morony,et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.
[52] K. Ikeda,et al. Transforming Growth Factor-β Stimulates the Production of Osteoprotegerin/Osteoclastogenesis Inhibitory Factor by Bone Marrow Stromal Cells* , 1998, The Journal of Biological Chemistry.
[53] K. Ikeda,et al. Immunological Characterization of Circulating Osteoprotegerin/Osteoclastogenesis Inhibitory Factor: Increased Serum Concentrations in Postmenopausal Women with Osteoporosis , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[54] J. Caamaño,et al. Osteopetrosis in mice lacking NF-κB1 and NF-κB2 , 1997, Nature Medicine.